{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:20:50Z","timestamp":1788898850032,"version":"build-2803163510"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00351442"],"award-info":[{"award-number":["RS-2024-00351442"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-25437095"],"award-info":[{"award-number":["RS-2025-25437095"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The DGIST start-up funds from the Ministry of Science and ICT"},{"name":"Korean Fund for Regenerative Medicine (KFRM) grant from the Korea government (the Ministry of Science and ICT, the Ministry of Health & Welfare)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) entails loss of substantia nigra dopamine (DA) neurons and \u03b1-synuclein pathology. Currently, no effective disease-modifying therapies have been developed. Human pluripotent stem cells (hPS cells) can generate DA neurons on scale, enabling human genetic PD modeling of mitochondrial, lysosomal and synaptic connection failure that leads to DA neuron degeneration. Clustered regularly interspaced short palindromic repeats (CRISPR) extends this human model by providing causal, isogenic interrogation and transcriptional regulation of PD genes and reporter knock-ins that support purification and high-content screening. hPS cell-based DA cell grafts can restore motor function yet face &gt;90% acute cell death and product heterogeneity in vivo post implantation. CRISPR enabled not only an in vivo cell survival screen to identify the cell death regulators but also a reporter-guided enrichment of DA neurons and chemogenetic control of grafted DA cell function in vivo. Here we summarize this progress and outline a practical road map to accelerate the development of precise human models and advanced hPS cell-based cell therapies for PD.<\/jats:p>","DOI":"10.1038\/s12276-026-01679-2","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T09:17:09Z","timestamp":1775812629000},"page":"993-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Human pluripotent stem cell engineering with CRISPR\u2013Cas9 for Parkinson\u2019s disease"],"prefix":"10.1038","volume":"58","author":[{"given":"Seung Bin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-8604","authenticated-orcid":false,"given":"Min Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0831-6881","authenticated-orcid":false,"given":"Tae Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su, D. et al. Projections for prevalence of Parkinsonas disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388, e080952 (2025).","journal-title":"BMJ"},{"key":"1679_CR2","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u20132303 (2021).","journal-title":"Lancet"},{"key":"1679_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Primers 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1111\/febs.14607","volume":"285","author":"DJ Surmeier","year":"2018","unstructured":"Surmeier, D. J. Determinants of dopaminergic neuron loss in Parkinson\u2019s disease. FEBS J. 285, 3657\u20133668 (2018).","journal-title":"FEBS J."},{"key":"1679_CR5","volume":"2011","author":"JA Potashkin","year":"2010","unstructured":"Potashkin, J. A., Blume, S. R. & Runkle, N. K. Limitations of animal models of Parkinson\u2019s disease. Parkinsons Dis. 2011, 658083 (2010).","journal-title":"Parkinsons Dis."},{"key":"1679_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3389\/fcell.2020.00729","volume":"8","author":"TW Kim","year":"2020","unstructured":"Kim, T. W., Koo, S. Y. & Studer, L. Pluripotent stem cell therapies for Parkinson disease: present challenges and future opportunities. Front. Cell Dev. Biol. 8, 729 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1679_CR7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41556-019-0344-z","volume":"21","author":"M De Luca","year":"2019","unstructured":"De Luca, M. et al. Advances in stem cell research and therapeutic development. Nat. Cell Biol. 21, 801\u2013811 (2019).","journal-title":"Nat. Cell Biol."},{"key":"1679_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","volume":"27","author":"S Yamanaka","year":"2020","unstructured":"Yamanaka, S. Pluripotent stem cell-based cell therapy\u2014promise and challenges. Cell Stem Cell 27, 523\u2013531 (2020).","journal-title":"Cell Stem Cell"},{"key":"1679_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nrg3563","volume":"15","author":"V Tabar","year":"2014","unstructured":"Tabar, V. & Studer, L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat. Rev. Genet. 15, 82\u201392 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"1679_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.stem.2022.01.007","volume":"29","author":"H Okano","year":"2022","unstructured":"Okano, H. & Morimoto, S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell 29, 189\u2013208 (2022).","journal-title":"Cell Stem Cell"},{"key":"1679_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303041","volume":"13","author":"MS Kim","year":"2024","unstructured":"Kim, M. S., Kim, H. & Lee, G. Precision medicine in Parkinson\u2019s disease using induced pluripotent stem cells. Adv. Healthc. Mater. 13, e2303041 (2024).","journal-title":"Adv. Healthc. Mater."},{"key":"1679_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.15283\/ijsc23169","volume":"18","author":"MS Kim","year":"2025","unstructured":"Kim, M. S., Yoon, S., Choi, J., Kim, Y. J. & Lee, G. Stem cell-based approaches in Parkinson\u2019s disease research. Int. J. Stem Cells 18, 21\u201336 (2025).","journal-title":"Int. J. Stem Cells"},{"key":"1679_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.stem.2021.01.005","volume":"28","author":"TW Kim","year":"2021","unstructured":"Kim, T. W. et al. Biphasic activation of WNT signaling facilitates the derivation of midbrain dopamine neurons from hESCs for translational use. Cell Stem Cell 28, 343\u2013355 (2021).","journal-title":"Cell Stem Cell"},{"key":"1679_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.stem.2024.01.006","volume":"31","author":"S Park","year":"2024","unstructured":"Park, S. et al. Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson\u2019s disease. Cell Stem Cell 31, 278\u2013279 (2024).","journal-title":"Cell Stem Cell"},{"key":"1679_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nature23664","volume":"548","author":"T Kikuchi","year":"2017","unstructured":"Kikuchi, T. et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson\u2019s disease model. Nature 548, 592\u2013596 (2017).","journal-title":"Nature"},{"key":"1679_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.stem.2023.08.014","volume":"30","author":"A Kirkeby","year":"2023","unstructured":"Kirkeby, A. et al. Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson\u2019s disease, STEM-PD. Cell Stem Cell 30, 1299\u20131314 (2023).","journal-title":"Cell Stem Cell"},{"key":"1679_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.stem.2025.01.006","volume":"32","author":"J Jeon","year":"2025","unstructured":"Jeon, J. et al. Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson\u2019s disease. Cell Stem Cell 32, 343\u2013360 (2025).","journal-title":"Cell Stem Cell"},{"key":"1679_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2021.01.004","volume":"28","author":"J Piao","year":"2021","unstructured":"Piao, J. et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell 28, 217\u2013229 (2021).","journal-title":"Cell Stem Cell"},{"key":"1679_CR19","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N. Engl. J. Med. 382, 1926\u20131932 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1679_CR20","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41586-025-08845-y","volume":"641","author":"V Tabar","year":"2025","unstructured":"Tabar, V. et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson\u2019s disease. Nature 641, 978\u2013983 (2025).","journal-title":"Nature"},{"key":"1679_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","volume":"641","author":"N Sawamoto","year":"2025","unstructured":"Sawamoto, N. et al. Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease. Nature 641, 971\u2013977 (2025).","journal-title":"Nature"},{"key":"1679_CR22","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1016\/j.cell.2025.09.010","volume":"188","author":"JW Chang","year":"2025","unstructured":"Chang, J. W. et al. Phase 1\/2a clinical trial of hESC-derived dopamine progenitors in Parkinson\u2019s disease. Cell 188, 7036\u20137048 (2025).","journal-title":"Cell"},{"key":"1679_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/science.add8643","volume":"379","author":"JY Wang","year":"2023","unstructured":"Wang, J. Y. & Doudna, J. A. CRISPR technology: a decade of genome editing is only the beginning. Science 379, eadd8643 (2023).","journal-title":"Science"},{"key":"1679_CR24","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR\u2013Cas9 for genome engineering. Cell 157, 1262\u20131278 (2014).","journal-title":"Cell"},{"key":"1679_CR25","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","volume":"187","author":"M Pacesa","year":"2024","unstructured":"Pacesa, M., Pelea, O. & Jinek, M. Past, present, and future of CRISPR genome editing technologies. Cell 187, 1076\u20131100 (2024).","journal-title":"Cell"},{"key":"1679_CR26","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012188","volume":"13","author":"S Guhathakurta","year":"2021","unstructured":"Guhathakurta, S. et al. Targeted attenuation of elevated histone marks at SNCA alleviates alpha-synuclein in Parkinson\u2019s disease. EMBO Mol. Med. 13, e12188 (2021).","journal-title":"EMBO Mol. Med."},{"key":"1679_CR27","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","volume":"26","author":"B Kantor","year":"2018","unstructured":"Kantor, B. et al. Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD. Mol. Ther. 26, 2638\u20132649 (2018).","journal-title":"Mol. Ther."},{"key":"1679_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102084","volume":"35","author":"Z Sun","year":"2024","unstructured":"Sun, Z., Kantor, B. & Chiba-Falek, O. Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies. Mol. Ther. Nucleic Acids 35, 102084 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1679_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05330-6","volume":"13","author":"A Iannielli","year":"2022","unstructured":"Iannielli, A. et al. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications. Cell Death Dis. 13, 881 (2022).","journal-title":"Cell Death Dis."},{"key":"1679_CR30","doi-asserted-by":"publisher","first-page":"E180","DOI":"10.1073\/pnas.1711023115","volume":"115","author":"C Potting","year":"2018","unstructured":"Potting, C. et al. Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy. Proc. Natl Acad. Sci. USA 115, E180\u2013E189 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1679_CR31","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.stem.2024.06.001","volume":"31","author":"N Saurat","year":"2024","unstructured":"Saurat, N. et al. Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration. Cell Stem Cell 31, 1162\u20131174 (2024).","journal-title":"Cell Stem Cell"},{"key":"1679_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s10517-018-4174-y","volume":"165","author":"AS Vetchinova","year":"2018","unstructured":"Vetchinova, A. S. et al. Cytogenetic analysis of the results of genome editing on the cell model of Parkinson\u2019s disease. Bull. Exp. Biol. Med. 165, 378\u2013381 (2018).","journal-title":"Bull. Exp. Biol. Med."},{"key":"1679_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60273-2","volume":"10","author":"SC Vermilyea","year":"2020","unstructured":"Vermilyea, S. C. et al. In vitro CRISPR\/Cas9-directed gene editing to model LRRK2 G2019S Parkinson\u2019s disease in common marmosets. Sci. Rep. 10, 3447 (2020).","journal-title":"Sci. Rep."},{"key":"1679_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2021.102354","volume":"53","author":"A Beylina","year":"2021","unstructured":"Beylina, A., Langston, R. G., Rosen, D., Reed, X. & Cookson, M. R. Generation of fourteen isogenic cell lines for Parkinson\u2019s disease-associated leucine-rich repeat kinase (LRRK2). Stem Cell Res. 53, 102354 (2021).","journal-title":"Stem Cell Res."},{"key":"1679_CR35","doi-asserted-by":"publisher","unstructured":"Bernal-Conde, L. D. et al. \u03b1-Synuclein gene alterations modulate tyrosine hydroxylase in human iPSC-derived neurons in a Parkinson\u2019s disease animal model. Life https:\/\/doi.org\/10.3390\/life14060728 (2024).","DOI":"10.3390\/life14060728"},{"key":"1679_CR36","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1093\/hmg\/ddx331","volume":"26","author":"SM Heman-Ackah","year":"2017","unstructured":"Heman-Ackah, S. M. et al. \u03b1-Synuclein induces the unfolded protein response in Parkinson\u2019s disease SNCA triplication iPSC-derived neurons. Hum. Mol. Genet. 26, 4441\u20134450 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"1679_CR37","doi-asserted-by":"publisher","unstructured":"Tagliafierro, L. et al. Lentiviral vector platform for the efficient delivery of epigenome-editing tools into human induced pluripotent stem cell-derived disease models. J. Vis. Exp. https:\/\/doi.org\/10.3791\/59241 (2019).","DOI":"10.3791\/59241"},{"key":"1679_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2022.102806","volume":"62","author":"CX Chen","year":"2022","unstructured":"Chen, C. X. et al. Generation of homozygous PRKN, PINK1 and double PINK1\/PRKN knockout cell lines from healthy induced pluripotent stem cells using CRISPR\/Cas9 editing. Stem Cell Res. 62, 102806 (2022).","journal-title":"Stem Cell Res."},{"key":"1679_CR39","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.29434","volume":"38","author":"J Pu","year":"2023","unstructured":"Pu, J. et al. Parkin maintains robust pacemaking in human induced pluripotent stem cell-derived A9 dopaminergic neurons. Mov. Disord. 38, 1273\u20131281 (2023).","journal-title":"Mov. Disord."},{"key":"1679_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.28810","volume":"37","author":"J Jarazo","year":"2022","unstructured":"Jarazo, J. et al. Parkinson\u2019s disease phenotypes in patient neuronal cultures and brain organoids improved by 2-hydroxypropyl-\u03b2-cyclodextrin treatment. Mov. Disord. 37, 80\u201394 (2022).","journal-title":"Mov. Disord."},{"key":"1679_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107044","volume":"26","author":"DA Beccano-Kelly","year":"2023","unstructured":"Beccano-Kelly, D. A. et al. Calcium dysregulation combined with mitochondrial failure and electrophysiological maturity converge in Parkinson\u2019s iPSC-dopamine neurons. iScience 26, 107044 (2023).","journal-title":"iScience"},{"key":"1679_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2022.102733","volume":"60","author":"F Zafar","year":"2022","unstructured":"Zafar, F., Nallur Srinivasaraghavan, V., Yang Chen, M., Alejandra Morato Torres, C. & Schule, B. Isogenic human SNCA gene dosage induced pluripotent stem cells to model Parkinson\u2019s disease. Stem Cell Res. 60, 102733 (2022).","journal-title":"Stem Cell Res."},{"key":"1679_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.stemcr.2019.12.005","volume":"14","author":"T Ahfeldt","year":"2020","unstructured":"Ahfeldt, T. et al. Pathogenic pathways in early-onset autosomal recessive Parkinson\u2019s disease discovered using isogenic human dopaminergic neurons. Stem Cell Rep. 14, 75\u201390 (2020).","journal-title":"Stem Cell Rep."},{"key":"1679_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43080-2","volume":"9","author":"C Calatayud","year":"2019","unstructured":"Calatayud, C. et al. CRISPR\/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons. Sci. Rep. 9, 6811 (2019).","journal-title":"Sci. Rep."},{"key":"1679_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.817198","volume":"16","author":"A Rakovic","year":"2022","unstructured":"Rakovic, A. et al. Electrophysiological properties of induced pluripotent stem cell-derived midbrain dopaminergic neurons correlate with expression of tyrosine hydroxylase. Front. Cell. Neurosci. 16, 817198 (2022).","journal-title":"Front. Cell. Neurosci."},{"key":"1679_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-021-00771-0","volume":"14","author":"M Yokota","year":"2021","unstructured":"Yokota, M. et al. Establishment of an in vitro model for analyzing mitochondrial ultrastructure in PRKN-mutated patient iPSC-derived dopaminergic neurons. Mol. Brain 14, 58 (2021).","journal-title":"Mol. Brain"},{"key":"1679_CR47","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1016\/j.cell.2024.05.030","volume":"187","author":"TW Kim","year":"2024","unstructured":"Kim, T. W. et al. TNF\u2013NF-\u03baB\u2013p53 axis restricts in vivo survival of hPSC-derived dopamine neurons. Cell 187, 3671\u20133689 (2024).","journal-title":"Cell"},{"key":"1679_CR48","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-023-06300-4","volume":"619","author":"TY Park","year":"2023","unstructured":"Park, T. Y. et al. Co-transplantation of autologous Treg cells in a cell therapy for Parkinson\u2019s disease. Nature 619, 606\u2013615 (2023).","journal-title":"Nature"},{"key":"1679_CR49","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4103\/NRR.NRR-D-24-01394","volume":"21","author":"TW Kim","year":"2026","unstructured":"Kim, T. W. Human stem cell-based cell replacement therapy for Parkinson\u2019s disease: enhancing the survival of postmitotic dopamine neuron grafts. Neural Regen. Res. 21, 689\u2013690 (2026).","journal-title":"Neural Regen. Res."},{"key":"1679_CR50","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41422-024-00971-y","volume":"34","author":"TY Park","year":"2024","unstructured":"Park, T. Y., Jeon, J., Cha, Y. & Kim, K. S. Past, present, and future of cell replacement therapy for Parkinson\u2019s disease: a novel emphasis on host immune responses. Cell Res. 34, 479\u2013492 (2024).","journal-title":"Cell Res."},{"key":"1679_CR51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41551-022-00987-y","volume":"7","author":"S Skidmore","year":"2023","unstructured":"Skidmore, S. & Barker, R. A. Challenges in the clinical advancement of cell therapies for Parkinson\u2019s disease. Nat. Biomed. Eng. 7, 370\u2013386 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"1679_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-023-00381-y","volume":"27","author":"P Pinjala","year":"2023","unstructured":"Pinjala, P. et al. CRISPR\/Cas9 assisted stem cell therapy in Parkinson\u2019s disease. Biomater. Res. 27, 46 (2023).","journal-title":"Biomater. Res."},{"key":"1679_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10571-019-00761-w","volume":"40","author":"F Safari","year":"2020","unstructured":"Safari, F. et al. CRISPR system: a high-throughput toolbox for research and treatment of Parkinson\u2019s disease. Cell. Mol. Neurobiol. 40, 477\u2013493 (2020).","journal-title":"Cell. Mol. Neurobiol."},{"key":"1679_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41531-019-0078-4","volume":"5","author":"LM Smits","year":"2019","unstructured":"Smits, L. M. et al. Modeling Parkinson\u2019s disease in midbrain-like organoids. NPJ Parkinsons Dis. 5, 5 (2019).","journal-title":"NPJ Parkinsons Dis."},{"key":"1679_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104940","volume":"141","author":"S Harjuhaahto","year":"2020","unstructured":"Harjuhaahto, S. et al. ALS and Parkinson\u2019s disease genes CHCHD10 and CHCHD2 modify synaptic transcriptomes in human iPSC-derived motor neurons. Neurobiol. Dis. 141, 104940 (2020).","journal-title":"Neurobiol. Dis."},{"key":"1679_CR56","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/hmg\/ddy413","volume":"28","author":"W Zhou","year":"2019","unstructured":"Zhou, W. et al. PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction. Hum. Mol. Genet. 28, 1100\u20131116 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"1679_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2021.102469","volume":"55","author":"L Schwarz","year":"2021","unstructured":"Schwarz, L., Casadei, N. & Fitzgerald, J. C. Generation of R272Q, S156A and K572R RHOT1\/Miro1 point mutations in iPSCs from a healthy individual using FACS-assisted CRISPR\/Cas9 genome editing. Stem Cell Res. 55, 102469 (2021).","journal-title":"Stem Cell Res."},{"key":"1679_CR58","doi-asserted-by":"publisher","first-page":"103085","DOI":"10.1016\/j.scr.2023.103085","volume":"69","author":"A Chemla","year":"2023","unstructured":"Chemla, A. et al. Generation of two induced pluripotent stem cell lines and the corresponding isogenic controls from Parkinson\u2019s disease patients carrying the heterozygous mutations c.1290A > G (p.T351A) or c.2067A > G (p.T610A) in the RHOT1 gene encoding Miro1. Stem Cell Res. 69, 103085 (2023).","journal-title":"Stem Cell Res."},{"key":"1679_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1152503","volume":"17","author":"F Mubariz","year":"2023","unstructured":"Mubariz, F. et al. Deregulation of mTORC1\u2013TFEB axis in human iPSC model of GBA1-associated Parkinson\u2019s disease. Front. Neurosci. 17, 1152503 (2023).","journal-title":"Front. Neurosci."},{"key":"1679_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2022.102919","volume":"64","author":"X-QC Chen","year":"2022","unstructured":"Chen, X.-Q. C. et al. Generation of patient-derived pluripotent stem cell-lines and CRISPR modified isogenic controls with mutations in the Parkinson\u2019s associated GBA gene. Stem Cell Res. 64, 102919 (2022).","journal-title":"Stem Cell Res."},{"key":"1679_CR61","doi-asserted-by":"publisher","unstructured":"Wulansari, N. et al. Neurodevelopmental defects and neurodegenerative phenotypes in human brain organoids carrying Parkinson\u2019s disease-linked DNAJC6 mutations. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abb1540 (2021).","DOI":"10.1126\/sciadv.abb1540"},{"key":"1679_CR62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2318943121","volume":"121","author":"N Mohd Rafiq","year":"2024","unstructured":"Mohd Rafiq, N., Fujise, K., Rosenfeld, M. S., Xu, P. & De Camilli, P. Parkinsonism Sac domain mutation in synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons. Proc. Natl Acad. Sci. USA 121, e2318943121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1679_CR63","doi-asserted-by":"publisher","unstructured":"Barbuti, P. et al. Using high-content screening to generate single-cell gene-corrected patient-derived IPS clones reveals excess \u03b1-synuclein with familial Parkinson\u2019s disease point mutation A30P. Cells https:\/\/doi.org\/10.3390\/cells9092065 (2020).","DOI":"10.3390\/cells9092065"},{"key":"1679_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01505-x","volume":"11","author":"PA Barbuti","year":"2021","unstructured":"Barbuti, P. A. et al. Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function. Sci. Rep. 11, 21946 (2021).","journal-title":"Sci. Rep."},{"key":"1679_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab223","volume":"3","author":"NV Mohamed","year":"2021","unstructured":"Mohamed, N. V. et al. Midbrain organoids with an SNCA gene triplication model key features of synucleinopathy. Brain Commun. 3, fcab223 (2021).","journal-title":"Brain Commun."},{"key":"1679_CR66","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/ejn.14286","volume":"49","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. Eur. J. Neurosci. 49, 510\u2013524 (2019).","journal-title":"Eur. J. Neurosci."},{"key":"1679_CR67","doi-asserted-by":"publisher","unstructured":"Inoue, S., Nishimura, K., Gima, S., Nakano, M. & Takata, K. CRISPR\u2013Cas9-edited SNCA knockout human induced pluripotent stem cell-derived dopaminergic neurons and their vulnerability to neurotoxicity. Biol. Pharm. Bull. https:\/\/doi.org\/10.1248\/bpb.b22-00839 (2023).","DOI":"10.1248\/bpb.b22-00839"},{"key":"1679_CR68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.scr.2017.08.013","volume":"24","author":"X Qing","year":"2017","unstructured":"Qing, X. et al. CRISPR\/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and \u03b1-synuclein modulation in dopaminergic neurons. Stem Cell Res. 24, 44\u201350 (2017).","journal-title":"Stem Cell Res."},{"key":"1679_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.stemcr.2018.12.011","volume":"12","author":"A di Domenico","year":"2019","unstructured":"di Domenico, A. et al. Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson\u2019s disease. Stem Cell Rep. 12, 213\u2013229 (2019).","journal-title":"Stem Cell Rep."},{"key":"1679_CR70","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s13287-021-02585-2","volume":"12","author":"KH Chang","year":"2021","unstructured":"Chang, K. H. et al. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation. Stem Cell Res. Ther. 12, 508 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"1679_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2020.101804","volume":"45","author":"S Chen","year":"2020","unstructured":"Chen, S. et al. Generation of two LRRK2 homozygous knockout human induced pluripotent stem cell lines using CRISPR\/Cas9. Stem Cell Res. 45, 101804 (2020).","journal-title":"Stem Cell Res."},{"key":"1679_CR72","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018101196","volume":"38","author":"MY Chang","year":"2019","unstructured":"Chang, M. Y. et al. LIN28A loss of function is associated with Parkinson\u2019s disease pathogenesis. EMBO J. 38, e101196 (2019).","journal-title":"EMBO J."},{"key":"1679_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2021.102506","volume":"55","author":"MC Mazza","year":"2021","unstructured":"Mazza, M. C., Beilina, A., Roosen, D. A., Hauser, D. & Cookson, M. R. Generation of iPSC line from a Parkinson patient with PARK7 mutation and CRISPR-edited Gibco human episomal iPSC line to mimic PARK7 mutation. Stem Cell Res. 55, 102506 (2021).","journal-title":"Stem Cell Res."},{"key":"1679_CR74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-022-00560-w","volume":"17","author":"K Chen","year":"2022","unstructured":"Chen, K. et al. LRP1 is a neuronal receptor for \u03b1-synuclein uptake and spread. Mol. Neurodegener. 17, 57 (2022).","journal-title":"Mol. Neurodegener."},{"key":"1679_CR75","doi-asserted-by":"publisher","first-page":"19317","DOI":"10.1074\/jbc.RA118.005498","volume":"293","author":"Y Jiang","year":"2018","unstructured":"Jiang, Y. et al. Zinc finger E-box-binding homeobox 1 (ZEB1) is required for neural differentiation of human embryonic stem cells. J. Biol. Chem. 293, 19317\u201319329 (2018).","journal-title":"J. Biol. Chem."},{"key":"1679_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/srep37540","volume":"6","author":"A Rubio","year":"2016","unstructured":"Rubio, A. et al. Rapid and efficient CRISPR\/Cas9 gene inactivation in human neurons during human pluripotent stem cell differentiation and direct reprogramming. Sci. Rep. 6, 37540 (2016).","journal-title":"Sci. Rep."},{"key":"1679_CR77","doi-asserted-by":"publisher","unstructured":"Chung, S. K. & Lee, S. Y. Advances in gene therapy techniques to treat LRRK2 gene mutation. Biomolecules https:\/\/doi.org\/10.3390\/biom12121814 (2022).","DOI":"10.3390\/biom12121814"},{"key":"1679_CR78","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/nn.4070","volume":"18","author":"L Brichta","year":"2015","unstructured":"Brichta, L. et al. Identification of neurodegenerative factors using translatome-regulatory network analysis. Nat. Neurosci. 18, 1325\u20131333 (2015).","journal-title":"Nat. Neurosci."},{"key":"1679_CR79","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.stem.2019.08.013","volume":"25","author":"M Riessland","year":"2019","unstructured":"Riessland, M. et al. Loss of SATB1 induces p21-dependent cellular senescence in post-mitotic dopaminergic neurons. Cell Stem Cell 25, 514\u2013530 (2019).","journal-title":"Cell Stem Cell"},{"key":"1679_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14077","volume":"23","author":"T Russo","year":"2024","unstructured":"Russo, T. et al. The SATB1\u2013MIR22\u2013GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons. Aging Cell 23, e14077 (2024).","journal-title":"Aging Cell"},{"key":"1679_CR81","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.stem.2023.05.015","volume":"30","author":"MS Kim","year":"2023","unstructured":"Kim, M. S. et al. Advanced human iPSC-based preclinical model for Parkinson\u2019s disease with optogenetic alpha-synuclein aggregation. Cell Stem Cell 30, 973\u2013986 (2023).","journal-title":"Cell Stem Cell"},{"key":"1679_CR82","doi-asserted-by":"publisher","unstructured":"Cardo, L. F., Monzon-Sandoval, J., Li, Z., Webber, C. & Li, M. Single-cell transcriptomics and in vitro lineage tracing reveals differential susceptibility of human iPSC-derived midbrain dopaminergic neurons in a cellular model of Parkinson\u2019s disease. Cells https:\/\/doi.org\/10.3390\/cells12242860 (2023).","DOI":"10.3390\/cells12242860"},{"key":"1679_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/srep28420","volume":"6","author":"SM Heman-Ackah","year":"2016","unstructured":"Heman-Ackah, S. M., Bassett, A. R. & Wood, M. J. Precision modulation of neurodegenerative disease-related gene expression in human iPSC-derived neurons. Sci. Rep. 6, 28420 (2016).","journal-title":"Sci. Rep."},{"key":"1679_CR84","doi-asserted-by":"publisher","first-page":"17796","DOI":"10.1038\/s41598-023-45078-3","volume":"13","author":"D Sastre","year":"2023","unstructured":"Sastre, D. et al. Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson's disease. Sci. Rep. 13, 17796 (2023).","journal-title":"Sci. Rep."},{"key":"1679_CR85","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.stemcr.2017.08.026","volume":"9","author":"J Arias-Fuenzalida","year":"2017","unstructured":"Arias-Fuenzalida, J. et al. FACS-assisted CRISPR\u2013Cas9 genome editing facilitates Parkinson\u2019s disease modeling. Stem Cell Rep. 9, 1423\u20131431 (2017).","journal-title":"Stem Cell Rep."},{"key":"1679_CR86","doi-asserted-by":"publisher","unstructured":"Gandy, A. et al. An inducible luminescent system to explore Parkinson\u2019s disease-associated genes. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25179493 (2024).","DOI":"10.3390\/ijms25179493"},{"key":"1679_CR87","doi-asserted-by":"publisher","unstructured":"Nadtochy, J. A. et al. Transgenic iPSC Lines with genetically encoded mitotimer to study mitochondrial biogenesis in dopaminergic neurons with tauopathy. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines13030550 (2025).","DOI":"10.3390\/biomedicines13030550"},{"key":"1679_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj4767","volume":"10","author":"S Santhosh Kumar","year":"2024","unstructured":"Santhosh Kumar, S. et al. Sequential CRISPR screening reveals partial NatB inhibition as a strategy to mitigate alpha-synuclein levels in human neurons. Sci. Adv. 10, eadj4767 (2024).","journal-title":"Sci. Adv."},{"key":"1679_CR89","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"M Parmar","year":"2020","unstructured":"Parmar, M., Grealish, S. & Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21, 103\u2013115 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"1679_CR90","doi-asserted-by":"publisher","unstructured":"Xu, P. et al. Human midbrain dopaminergic neuronal differentiation markers predict cell therapy outcomes in a Parkinson\u2019s disease model. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI156768 (2022).","DOI":"10.1172\/JCI156768"},{"key":"1679_CR91","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.stem.2023.02.007","volume":"30","author":"Z You","year":"2023","unstructured":"You, Z. et al. Mapping of clonal lineages across developmental stages in human neural differentiation. Cell Stem Cell 30, 473\u2013487 (2023).","journal-title":"Cell Stem Cell"},{"key":"1679_CR92","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.stem.2016.03.014","volume":"18","author":"Y Chen","year":"2016","unstructured":"Chen, Y. et al. Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson\u2019s disease. Cell Stem Cell 18, 817\u2013826 (2016).","journal-title":"Cell Stem Cell"},{"key":"1679_CR93","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.cell.2024.01.049","volume":"187","author":"JH Yang","year":"2024","unstructured":"Yang, J. H. et al. Loss of epigenetic information as a cause of mammalian aging. Cell 187, 1312\u20131313 (2024).","journal-title":"Cell"},{"key":"1679_CR94","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yjmcc.2018.11.014","volume":"127","author":"RG Morgan","year":"2019","unstructured":"Morgan, R. G. et al. Induced Trf2 deletion leads to aging vascular phenotype in mice associated with arterial telomere uncapping, senescence signaling, and oxidative stress. J. Mol. Cell. Cardiol. 127, 74\u201382 (2019).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1679_CR95","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.stem.2013.11.006","volume":"13","author":"JD Miller","year":"2013","unstructured":"Miller, J. D. et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13, 691\u2013705 (2013).","journal-title":"Cell Stem Cell"},{"key":"1679_CR96","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1038\/s41593-024-01775-4","volume":"27","author":"A Bayati","year":"2024","unstructured":"Bayati, A. et al. Modeling Parkinson\u2019s disease pathology in human dopaminergic neurons by sequential exposure to \u03b1-synuclein fibrils and proinflammatory cytokines. Nat. Neurosci. 27, 2401\u20132416 (2024).","journal-title":"Nat. Neurosci."},{"key":"1679_CR97","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41531-025-01175-w","volume":"11","author":"H Kim","year":"2025","unstructured":"Kim, H. et al. A novel peptide-based strategy to enhance GBA1 expression for treating Parkinson\u2019s disease. NPJ Parkinsons Dis. 11, 323 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"1679_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22113-3","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim, S., Wong, Y. C., Gao, F. & Krainc, D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson\u2019s disease. Nat. Commun. 12, 1807 (2021).","journal-title":"Nat. Commun."},{"key":"1679_CR99","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fcell.2020.00359","volume":"8","author":"LM Smits","year":"2020","unstructured":"Smits, L. M. & Schwamborn, J. C. Midbrain organoids: a new tool to investigate Parkinson\u2019s disease. Front. Cell Dev. Biol. 8, 359 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1679_CR100","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1038\/s44318-025-00494-1","volume":"44","author":"A Fiorenzano","year":"2025","unstructured":"Fiorenzano, A. et al. Advances, challenges, and opportunities of human midbrain organoids for modelling of the dopaminergic system. EMBO J. 44, 4181\u20134195 (2025).","journal-title":"EMBO J."},{"key":"1679_CR101","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.stemcr.2019.01.020","volume":"12","author":"H Kim","year":"2019","unstructured":"Kim, H. et al. Modeling G2019S-LRRK2 sporadic Parkinson\u2019s disease in 3D midbrain organoids. Stem Cell Rep. 12, 518\u2013531 (2019).","journal-title":"Stem Cell Rep."},{"key":"1679_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102922","volume":"113","author":"K Pandya","year":"2026","unstructured":"Pandya, K. & Kumar, D. CRISPR\/Cas genome editing for neurodegenerative diseases: mechanisms, therapeutic advances, and clinical prospects. Ageing Res. Rev. 113, 102922 (2026).","journal-title":"Ageing Res. Rev."},{"key":"1679_CR103","doi-asserted-by":"publisher","first-page":"234","DOI":"10.15283\/ijsc22171","volume":"16","author":"JC Park","year":"2023","unstructured":"Park, J. C., Kim, K. T., Jang, H. K. & Cha, H. J. Transition substitution of desired bases in human pluripotent stem cells with base editors: a step-by-step guide. Int. J. Stem Cells 16, 234\u2013243 (2023).","journal-title":"Int. J. Stem Cells"},{"key":"1679_CR104","doi-asserted-by":"publisher","first-page":"79","DOI":"10.15283\/ijsc.2011.4.2.79","volume":"4","author":"VJ Patricio","year":"2011","unstructured":"Patricio, V. J. Science and ethics: bridge to the future for regenerative medicine. Int. J. Stem Cells 4, 79\u201384 (2011).","journal-title":"Int. J. Stem Cells"},{"key":"1679_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2023.103125","volume":"69","author":"N Kozhushko","year":"2023","unstructured":"Kozhushko, N., Beilina, A. & Cookson, M. R. Generation of gene-corrected isogenic controls from Parkinson\u2019s disease patient iPSC lines carrying the pathogenic SNCA p.A53T variant. Stem Cell Res. 69, 103125 (2023).","journal-title":"Stem Cell Res."},{"key":"1679_CR106","doi-asserted-by":"publisher","unstructured":"Santhosh Kumar, S. et al. Sequential CRISPR screening reveals partial NatB inhibition as a strategy to mitigate alpha-synuclein levels in human neurons. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.adj4767 (2024).","DOI":"10.1126\/sciadv.adj4767"},{"key":"1679_CR107","doi-asserted-by":"publisher","unstructured":"Jarazo, J. et al. Parkinson\u2019s disease phenotypes in patient neuronal cultures and brain organoids improved by 2-hydroxypropyl-\u03b2-cyclodextrin treatment. Mov. Dis. https:\/\/doi.org\/10.1002\/mds.28810 (2022).","DOI":"10.1002\/mds.28810"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01679-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01679-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01679-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:06:54Z","timestamp":1782716814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01679-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":107,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01679-2","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}